Utah Insurance Department Issues Bulletin Regarding Prescription Drug Price Transparency Act; Contact Information Due June 1, 2020

May 11, 2020

The Utah Insurance Department ("Department") recently issued a bulletin to drug manufacturers regarding the state's Prescription Drug Price Transparency Act ("Act"), Utah Code Section 31A-47-103. The Act requires pharmacy drug manufacturers to report certain drug price information to the Department.

According to the bulletin, drug manufacturers should provide their company contact information to the Department on or before June 1, 2020. Manufacturers should submit the following via e-mail to uid.healthresearch@utah.gov, with "Bulletin 2020 Contact Information" in the subject line:

  • Company name
  • Company EIN Number
  • Contact Person
  • Contact Mailing Address
  • Contact Phone
  • Contact E-mail Address

The bulletin states that the Department will "work with pharmacy drug manufacturers and other stakeholders to develop a reporting template, an administrative rule, and a standard method of securely receiving and storing the information provided" by manufacturers.

The Department expects to begin accepting reports on January 1, 2021, and reports will not be required prior to that date.

For more information, and to view a copy of the bulletin and the Act, please visit Utah's Price/Cost Disclosure section of the Transparency and Limitations Database.


If you are interested in receiving updates relevant to Life Sciences compliance, please contact us for two weeks of complimentary access to all Porzio Compliance Digest InfoCenters. Topics include US and International transparency, US Enforcement Action, HCP Authorities/Restrictions and Licensing Distribution: Trade and Sample.

More Resources